Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Moban
Synonyms :
molindone
Class :
Antipsychotic Agents (First Generation [Typical]), Neurotoxic agents, Psychotropic Drugs
Dosage Forms & StrengthsÂ
TabletÂ
5mgÂ
10mgÂ
25mgÂ
50mgÂ
Indicated for the treatment of schizophrenia:
Initial dose:
50-75mg orally once a day
May titrate up or down dependent on the severity of symptoms and individual patient response; escalate to 100 mg daily in 3-4 days
Maintenance dose:
Mild: 5 to 15mg orally thrice a day
Moderate: 10 to 25mg orally thrice a day
Severe: 225mg/day orally when needed
Dose Adjustments
Start treatment at a lower dosage in aged and impaired individuals
Safety and efficacy not establishedÂ
Use starting doses that are lower than normalÂ
may decrease the therapeutic effect of antiparkinson agents
may decrease the therapeutic effect of antiparkinson agents
may decrease the therapeutic effect of antiparkinson agents
may decrease the therapeutic effect of antiparkinson agents
may decrease the therapeutic effect of antiparkinson agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the constipating effect of anticholinergic agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the toxic effect of Seizure Threshold Lowering Potential Agents
may increase the toxic effect of Seizure Threshold Lowering Potential Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the anticholinergic effect of Anticholinergic Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the anticholinergic effect of Anticholinergic Agents
may increase the constipating effect of Anticholinergic Agents
may increase the anticholinergic effect of Anticholinergic Agents
may increase the anticholinergic effect of Anticholinergic Agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the anticholinergic effect of Anticholinergic Agents
may increase the anticholinergic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
- may increase the toxic effect of antipsychotic agents
- may increase the toxic effect of antipsychotic agents
- may increase the toxic effect of antipsychotic agents
- may increase the toxic effect of antipsychotic agents
- may increase the toxic effect of antipsychotic agents
may increase the toxic effect of antipsychotic agents
may increase the toxic effect of antipsychotic agents
may increase the toxic effect of antipsychotic agents
may increase the toxic effect of antipsychotic agents
may increase the toxic effect of antipsychotic agents
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may increase the toxic effect of CNS depressants
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Anticholinergic Agents
When molindone is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Actions and Spectrum:Â
Frequency not defined Â
DepressionÂ
EuphoriaÂ
AkathisiaÂ
DystoniaÂ
TachycardiaÂ
Dry mouthÂ
DrowsinessÂ
HyperactivityÂ
Extrapyramidal symptomsÂ
Parkinson syndromeÂ
Tardive dyskineisaÂ
NauseaÂ
SalivationÂ
AmenorrheaÂ
GalactorrheaÂ
LeukopeniaÂ
Lens opacities and pigmentary retinopathyÂ
Urinary retentionÂ
PriapismÂ
GynecomastiaÂ
Libido increasedÂ
Alteration in liver function testsÂ
T-wave changes (transient, rare)Â
RashÂ
Black box warning:Â
molindone carries a black box warning for increased mortality in elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs like molindone are at an increased risk of death compared to placeboÂ
Contraindications/caution:Â
Contraindications:Â
molindone has several contraindications, which are as follows:Â
Caution:Â
molindone should be used with caution in patients with certain medical conditions or specific populations, such as:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
The pharmacodynamics of molindone is related to its mechanism of action as a D2 dopamine receptor antagonist in the brain. By blocking the activity of these receptors, molindone reduces the levels of dopamine neurotransmission, which is believed to be involved in the pathophysiology of psychosis.Â
Pharmacokinetics:Â
AbsorptionÂ
molindone is rapidly and completely absorbed after oral administration, with peak plasma concentrations reached within 2-3 hours.Â
DistributionÂ
molindone is highly protein-bound, with approximately 76% bound to plasma proteins.Â
MetabolismÂ
molindone is extensively metabolized in the liver, primarily via the cytochrome P450 (CYP) 2D6 enzyme.Â
Elimination and ExcretionÂ
The half-life of molindone is approximately 15 hours. The metabolites of molindone are excreted primarily in the urine, with approximately 2-3% excreted unchanged in the urine and feces.Â
Administration:Â
Patient information leafletÂ
Generic Name: molindoneÂ
Why do we use molindone?Â
molindone is an antipsychotic medication that is primarily used for the treatment of schizophrenia and other psychotic disorders. It may also be used to manage severe behavioral disturbances in patients with dementia, such as aggression and agitation, as well as to control tics and vocalizations associated with Tourette’s syndromeÂ